Results 21 to 30 of about 8,656 (193)
Metabolites, 2022 The presence of residual cardiovascular disease (CVD) risk is a current dilemma in clinical practice; indeed, despite optimal management and treatment, a considerable proportion of patients still undergo major CV events.
Jelena Vekic +6 more
doaj +1 more source
Cell Reports, 2014 Incretins, hormones released by the gut after meal ingestion, are essential for maintaining systemic glucose homeostasis by stimulating insulin secretion.
Ghupurjan Gheni +21 more
doaj +1 more source
Genetic variants affecting incretin sensitivity and incretin secretion [PDF]
Diabetologia, 2010 Recent genome-wide association studies identified several novel risk genes for type 2 diabetes. The majority of these type 2 diabetes risk variants confer impaired pancreatic beta cell function. Though the molecular mechanisms by which common genetic variation within these loci affects beta cell function are not completely understood, risk variants may
K, Müssig +4 more
openaire +2 more sources
orlistat improves release of gut hormones increasing satiety in obese women
Ожирение и метаболизм, 2014 Orlistat, which reduces fat absorption by inhibiting intestinal lipase is a registered drug for obesity pharmacotherapy. Meta-analyzes indicate various positive metabolic effects of orlistat, including improvements in glucose and lipid metabolism ...
Teona Albertovna Shvangiradze
doaj +1 more source
Best Achievements in Clinical Medicine in Diabetes and Dyslipidemia in 2020 [PDF]
Endocrinology and Metabolism, 2021 Over the last two decades, our understanding of diabetes and treatment strategies have evolved tremendously, from scientific, mechanistic, and human perspectives.
Eun-Jung Rhee +2 more
doaj +1 more source
A view at postbariatric hypoglycemia by endocrinologist
Ожирение и метаболизм, 2022 The obesity epidemic has led to the growing number of bariatric operations and the expansion of indications for this operation as the most effective method of treatment, that’s why endocrinologists are increasingly faced the challenge of late ...
E. I. Kim +3 more
doaj +1 more source
Incretins, pregnancy, and gestational diabetes
, 2016 The number of pregnant women affected by gestational diabetes mellitus (GDM) is increasing among Caucasians, and East Asians. GDM also increases the risk for later advent of type 2 diabetes mellitus (T2DM), obesity, and cardiovascular disease in both ...
Nikolic D. +9 more
core +2 more sources
Exendin-4(1-32)K-Capric Acid, a Glucagon-Like Peptide-1 Receptor Agonist, Suppresses Food Intake via Arcuate Pro-Opiomelanocortin Neurons [PDF]
Endocrinology and MetabolismBackground Glucagon-like peptide-1 (GLP-1) is an incretin known for its anti-obesity effects, and several effective drugs targeting GLP-1 receptors (GLP-1Rs) have recently been developed to treat obesity.
Sujin Yoo +3 more
doaj +1 more source
Incretins today: multiple effects and therapeutic potential [PDF]
, 2019 Glucose-dependent insulinotropic peptide (GIP) and glucagon-like peptide-1 (GLP-1) are the incretin hormones initially discovered in the 1960s. GIP and GLP-1 have gained great scientific interest due to their properties in increasing insulin secretion ...
Varvara V. Veretyuk +2 more
core +1 more source